Pulmonary Medicine

Host: Jacob Sands, MD

Guest: Mark Awad, MD, PhD

What do we need to know about the role of biomarkers in non-small cell lung cancer? Dr. Mark Awad from the Dana-Farber Cancer Institute explains.

Guest: D. Ross Camidge, MD, PhD

With only two targeted therapy options available for RET rearranged advanced non-small cell lung cancer, how do we select the best approach? Dr. Ross Camidge, the Director of the Thoracic Oncology Clinical and Clinical Research Programs at the University of Colorado, discusses treatment options for NSCLC.

Guest: D. Ross Camidge, MD, PhD

After starting on a RET inhibitor, what do you do? Dr. Ross Camidge, the Director of the Thoracic Oncology Clinical and Clinical Research Programs at the University of Colorado, breaks down the progression of RET inhibitors in patients with non-small cell lung cancer and what tests should be utilized throughout the process.

Host: Jacob Sands, MD

Guest: Andrea B. McKee, MD

Lung cancer screening is one of the most critical components of reducing cancer mortality rates. Dr. Andrea McKee, Chair Emeritus in Radiation Oncology and Director of the Lung Screening Program at Lahey Hospital and Medical Center, joins Dr. Jacob Sands to discuss updates in lung screening.

Host: Jacob Sands, MD

Guest: Andrea B. McKee, MD

How can a lung screening program enhance the quality of care for patients with lung cancer? Dr. Andrea McKee, Chair Emeritus in Radiation Oncology and Director of the Lung Screening Program at Lahey Hospital and Medical Center, shares how she and her colleagues designed this program at Lahey Hospital and Medical Center.

Host: Jacob Sands, MD

Guest: Aaron S. Mansfield, MD

There are different treatment options available for early-stage mesothelioma, and there seem to be differences in standard practice from one center to the next. Joining Dr. Jacob Sands to share how he approaches the treatment of early-stage mesothelioma using the latest options is Dr. Aaron Mansfield, an Associate Professor of Oncology and Co-Director of Precision Cancer Therapeutics at Mayo Clinic in Rochester.

Host: Andrew Wilner, MD, FACP, FAAN

Guest: Jennifer Frontera, MD

Most commonly associated with respiratory symptoms, COVID-19 infections have led to a myriad of neurological symptoms such as encephalopathy and stroke. Dr. Andrew Wilner joins Dr. Jennifer Frontera, a neurocritical care specialist and professor of neurology at the NYU Grossman School of Medicine, to discuss obstacles that neurologists have faced during the COVID-19 pandemic.

Host: Andrew Wilner, MD, FACP, FAAN

Guest: Jennifer Frontera, MD

Although the impact of COVID-19 can be long-lasting, many have had similar effects, even if they aren’t diagnosed with the disease. Dr. Jennifer Frontera, a neurocritical care specialist and professor of neurology at the NYU Grossman School of Medicine, shares some insight on the neurological symptoms that patients with COVID-19 are facing.

Host: Jacob Sands, MD

Guest: Aaron S. Mansfield, MD

Mesothelioma is a cancer with limited treatment options, so how can we manage it in the first and second-line settings and beyond? Here with Dr. Jacob Sands to walk us through the various treatment approaches to mesothelioma is Dr. Aaron Mansfield, Associate Professor of Oncology and Co-Director of Precision Cancer Therapeutics at Mayo Clinic in Rochester.

Host: Paul Doghramji, MD

Guest: Sarojini Qasba, MD

With the World Health Organization’s goal to eliminate tuberculosis by 2030 quickly approaching, what can we be doing now to help us meet that goal? Joining Dr. Paul Doghramji to discuss three key factors and how the COVID-19 pandemic has impacted this global goal is Dr. Sonia Qasba, an infectious disease specialist at the Suburban Hospital in Bethesda, Maryland.